Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis
The Journal of Allergy and Clinical Immunology: In Practice · 2023-12 · 11 (12) · 3650-3661.e3
DOI: 10.1016/j.jaip.2023.07.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-12. Verfasst von Mark C Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, Md. Electroni…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Pulmonary Disease, Chronic Obstructive, Gastroesophageal Reflux. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
BACKGROUND: Severe asthma is complex; comorbidities may influence disease outcomes. OBJECTIVE: To assess mepolizumab effectiveness in patients with severe asthma and comorbidities. METHODS: REALITI-A was a 2-year international, prospective study enrolling adults with asthma newly prescribed mepolizumab (100 mg subcutaneously) at physician's discretion. This post hoc analysis assessed 1-year outcomes stratified by comorbidities at enrollment: chronic rhinosinusitis with nasal polyps (CRSwNP), gastroesophageal reflux disease (GERD), depression/anxiety, and chronic obstructive pulmonary disease (COPD). Outcomes included the rate of clinically significant asthma exacerbations (CSEs; requiring systemic corticosteroids and/or hospital/emergency room admission) between the 12 months pre- and post-mepolizumab treatment and changes from baseline in daily maintenance oral corticosteroid dose (mo 12), Asthma Control Questionnaire-5 score (mo 12) and forced expiratory volume in 1 second (FEV1; mo 9-12). RESULTS: At enrollment (n = 822), 321 of 822 (39%), 309 of 801 (39%), 203 of 785 (26%), and 81 of 808 (10%) patients had comorbid CRSwNP, GERD, depression/anxiety, and COPD, respectively. Post- versus pre-treatment across all comorbidity subgroups: the rate of CSEs decreased by 63% or more; among 298 (39%) patients on maintenance oral corticosteroids at baseline, median dose decreased by 50% or more; Asthma Control Questionnaire-5 score decreased by 0.63 or more points; FEV1 increased by 74 mL or more. Patients with versus without CRSwNP had the greatest improvements (eg, rate of CSEs decreased by 75%). Patients without GERD, depression/anxiety, or COPD had greater improvements than those with the respective comorbidities, except for FEV1 in patients with COPD. CONCLUSIONS: Mepolizumab improved disease outcomes in patients with severe asthma irrespective of comorbidities, with additional benefit for patients with CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, Md. Electronic address: mcl@jhmi.edu.
- Allergy and Respiratory Diseases, DIMI Department of Internal Medicine, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
- Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
- Department of Pulmonary Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Pole of Pneumology, ENT and Dermatology, Institute of Experimental and Clinical Research, UCLouvain, Brussels, Belgium.
- Biostatistics, GSK, Stevenage, UK.
- Real World Study Delivery, Value Evidence and Outcomes, Global Medical, GSK, Stevenage, UK.
Förderung
- GlaxoSmithKline
Zitieren
APA
Liu, M. C., Bagnasco, D., Matucci, A., Pilette, C., Price, R. G., Maxwell, A. C., Alfonso-Cristancho, R., Jakes, R. W., Lee, J. K., & Howarth, P. (2023). Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. The Journal of Allergy and Clinical Immunology: In Practice, 11(12), 3650-3661.e3. https://doi.org/10.1016/j.jaip.2023.07.024
Vancouver
Liu MC, Bagnasco D, Matucci A, Pilette C, Price RG, Maxwell AC, et al. Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(12):3650-3661.e3. doi:10.1016/j.jaip.2023.07.024
BibTeX
@article{Liu2023,
author = {Liu, Mark C and Bagnasco, Diego and Matucci, Andrea and Pilette, Charles and Price, Robert G and Maxwell, Aoife C and Alfonso-Cristancho, Rafael and Jakes, Rupert W and Lee, Jason K and Howarth, Peter},
title = {Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
volume = {11},
number = {12},
pages = {3650--3661.e3},
doi = {10.1016/j.jaip.2023.07.024}
}
EUVIMED